siRNA targeting myeloid cell leukemia sequence 1
US7514550B2 · kind B2 · utility
67Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 20, 2007 |
| Grant date | Apr 7, 2009 |
| Priority date | — |
| Expiry date | Sep 20, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.